暴露于免疫抑制治疗患者中肺孢子菌病的发病率
该回顾性队列分析在无HIV、艾滋病或癌症的成人中,识别暴露于免疫抑制剂、糖皮质激素或两者后的肺孢子菌病新发病例,共406例。总体5年发病率为0.012%(406/3,366,086),联合暴露组最高(0.199%),且联合暴露组相比未暴露组的相对风险为RR 122.5(95%CI 100.9-148.8)。作者认为对联合免疫抑制剂和糖皮质激素治疗的患者进行预防可能是有理由的。
要点
- 联合暴露组肺孢子菌病发病率最高,为0.199%。
- 联合暴露组相比未暴露组RR为122.5(95%CI 100.9-148.8)。
- 总体发病率很低,为0.012%(406/3,366,086)。
核心结论
- 暴露于免疫抑制剂患者的肺孢子菌病发病率非常低,对联合免疫抑制剂和糖皮质激素治疗的最高风险组进行预防可能是有理由的。
研究设计与样本
- 回顾性队列分析,纳入无HIV、艾滋病或癌症且暴露于免疫抑制剂、糖皮质激素治疗或两者的成人,识别肺孢子菌病新发病例。
主要发现
- 在处方免疫抑制剂、糖皮质激素或两者的患者中识别出406例新发病例。
- 总体肺孢子菌病发病率为0.012%(406/3,366,086)。
- 暴露于免疫抑制剂和糖皮质激素者的发病率最高(0.199%),其次为仅暴露于免疫抑制剂者(0.012%)、仅暴露于糖皮质激素者(0.008%)和两者均未暴露者(0.001%)(P < .001)。
- 联合暴露组相比两者均未暴露组的风险差为0.198%(95%CI 0.166%-0.230%),相比仅免疫抑制剂暴露组为0.188%(95%CI 0.155%-0.221%)。
- 联合暴露组相比两者均未暴露组的RR为122.5(95%CI 100.9-148.8),相比仅免疫抑制剂暴露组为RR 16.5(95%CI 7.3-37.4)。
临床怎么用
- 作者认为,对接受联合免疫抑制剂和糖皮质激素治疗的最高风险组患者进行预防可能是有理由的。
局限性
- 无法确认暴露的剂量和持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The decision to administer prophylaxis to patients receiving immunosuppression against pneumocystosis remains a dilemma. OBJECTIVE: To determine overall and age-specific 5-year pneumocystosis incidence within a population exposed to immunosuppressants. METHODS: Retrospective cohort analysis identifying incident pneumocystosis cases among adults without HIV, AIDS, or cancer exposed to immunosuppressant, corticosteroid therapy, or both. RESULTS: We identified 406 new cases among patients prescribed an immunosuppressant, corticosteroid, or both. Overall incidence of pneumocystosis was 0.012% (406/3,366,086). Incidence was highest in those exposed to immunosuppressant and corticosteroid medications (0.199%), followed by those exposed to immunosuppressant alone (0.012%), corticosteroid alone (0.008%), and neither medication (0.001%) (P < .001). The greatest risk differences were noted between groups exposed to immunosuppressant and corticosteroid compared with neither (0.198%, 95% confidence interval [CI] 0.166%-0.230%) or immunosuppressant alone (0.188%, 95% CI 0.155%-0.221%). The greatest relative risks (RRs) were noted among those receiving immunosuppressant and corticosteroid compared with those exposed to neither (RR 122.5, 95% CI 100.9-148.8) or immunosuppressant alone (RR 16.5, 95% CI 7.3-37.4). LIMITATIONS: We could not confirm dose and duration of exposures. CONCLUSION: Incidence of pneumocystosis among patients exposed to immunosuppressants is very low. Prophylaxis for patients receiving combination immunosuppressant and corticosteroid therapy, the group at highest risk, might be warranted.
引用
- Rekhtman S, Strunk A, Garg A, et al. Incidence of pneumocystosis among patients exposed to immunosuppression. J Am Acad Dermatol. 2019. PMID: 30639289. doi:10.1016/j.jaad.2018.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。